173 results about "Globin" patented technology

A preparation is provided which can be injected or implanted into the human or animal body, and which comprises, as main component, globin that is insoluble at physiological pH, biocompatible and sterile.

Implantable preparation comprising a material which can be obtained from globin that has been modified, especially chemically, to be, at least partially, soluble at physiological pH, the material being biocompatible, and biodegradable in the organism. The material may be soluble at physiological pH, or insoluble at that pH. The preparation may be in the form of a solution, suspension, paste, gel, film, sponge, powder or granules, or a solid implant. Application in particular to the healing, protection or filling of external skin wounds, the filling of wrinkles and skin flaws, the filling of tissue, as means for fixing prostheses or biomaterials, or means for preventing adhesion.

The invention provides a hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit. The hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit comprises an upper shell, a lower shell, an immunostrip, test paper and the like; a gold-labeled composite containing a hemoglobin monoclonal antibody, a hemoglobin-haptoglobin composite monoclonal antibody and a transferrin monoclonal antibody is scribed on a nitrocellulose membrane; 3 test lines, a quality control line (15) and a gold-labeled composite membrane scribing line (8) are arranged on the nitrocellulose membrane in parallel. The invention further provides a preparation method and a detection method of the hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit. The hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit is convenient and simple in operation, stable in performance and accurate in result, has a relatively good reference value for early diagnosis and identification of colorectal cancer or colon cancer tumor or other tumors with lower gastrointestinal bleeding symptoms in clinic, significantly improves the positive detection rate of digestive hemorrhagic diseases, is suitable for clinical hospital examination and household self-examination, and provides measures for large-scale general examination of such diseases.

The present invention provides methods for increasing endogenous globin expression in a subject, specifically γ-globin expression. The invention also provides compounds and medicaments for use in the methods. The methods are particularly useful for increasing fetal hemoglobin production in a subject, and can be used to treat various disorders, e.g., β thalassemia and sickle cell disease.

Intra-oral imaging apparatus and/or method embodiments can provide digital dental reflectance images used to identify selected areas of interest (AOI) within a dental region of interest (ROD having selected image characteristics for both hemo-globin's total concentration and oxygenation level. In one embodiment, reflectance images can determine relative total hemoglobin using at least a wavelength band that includes an isobestic wavelength for absorption coefficients of oxyhemoglobin (HbO₂) and deoxyhemoglobin (Hb). In one embodiment, intra-oral imaging apparatus and/or method embodiments can use reflectance images of a dental region at least at three wavelengths; a control logic processor for processing the reflectance images to determine relative tHb and its relative oxygenation level and/or identify disease areas having periodontal tissues condition; and a display for displaying periodontal tissues or a visual indication of the areas having selected imaging characteristic determined by the reflectance images.

A reagent capable of quickly and jointly detecting hemoglobin-haptogiobin compound in stool and occult blood in stool adopts the immunological principle and colloidal gold immune chromatographic technology and mainly comprises an immune test bar and a plastic piece. The reagent has great significance in clinical early diagnosis and identification of tumours with hemorrhage of lower digestive tract symptom like rectal cancer or colon cancer, etc., with simple method, convenient operation, stable performance and correct results. Because of the characteristics of quickness, simplicity and high accuracy, the reagent which is suitable for clinical medical examination and family self examination also provides means not only for screening the diseases of this category but also for diagnosing the diseases of this category in underdeveloped areas.

The invention discloses a probe with a nucleotide sequence complementary to human papilloma virus HPV DNA, a genotyping detection kit containing the probe and a gene chip preparation method thereof. The probe is selected from SEQ ID Nos: 1-21 and sequences complementary to SEQ ID Nos: 1-21. The kit includes a gene chip with at least one of the above-mentioned probes, a DNA sequence marked with biotin spots, a DNA sequence coding a part of β-globulin, and various primers selected from MY09/MY11. The gene chip of the kit is prepared through the steps of preparing DNA probes, fixing the probes, using sodium hydroxide to stop the reaction, and the like. The kit of the invention can quickly and accurately detect HPV infection and identify specific subtypes, is more suitable for Chinese people, and has great significance for early diagnosis, prevention, treatment and follow-up of cervical cancer.

The invention relates to a method for detecting human beta-globin gene mutation, in particular to a method for detecting the beta-globin gene mutation by a modified molecular beacon melting curve. The method comprises the following steps of: designing and preparing a corresponding modified molecular beacon in region of a beta-globin gene needing mutation detection; designing an upstream primer and a downstream primer on the periphery of the designed modified molecule beacon, and performing PCR amplification on fragments containing the region to be detected by using the upstream primer and the downstream primer; and after PCR amplification is finished, analyzing the melting curve, and judging whether a nucleotide sequence to be detected has the gene mutation and possible mutation types according to the change of the melting point of the modified molecular beacon.

The invention discloses a method for extracting hemoy lobin and superoxide dismutase from bloods of livestock, which comprises the steps that: after going through an anti-freezing treatment, the fresh bloods of livestock is centrifuged to collect corpuscles, and after hemolysis, heating treatment is carried out so as to extract the hemoy lobin and SOD crude extracted liquid; SOD refined products are obtained after the SOD crude extracted liquid goes through treatments of thermal denaturation, super-filtration concentration, fractionated precipitation of acetone and absorption by ion exchanger. The method of the invention has simple operation and low production cost, is suitable for large-scale industrialized production, and can be used for simultaneously extracting the SOD and hemoy lobin in the bloods of livestock, thereby achieving the highly effective recovery of a plurality of protein resources from the blood of livestock. The extracted hemoy lobin contains salts such as sodium chloride and potassium chloride, etc which are harmless to the human body without containing copper ions. Therefore, the extracted hemoy lobin can be served as food for human beings and livestock, and also can be used for further producing hemoy lobin products such as hemachrome and decolored globin, etc.

The invention discloses a manufacture method of hemachrome and discolored globin powder. The method comprises the steps that: after zymohydrolysis and equal point deposition of the raw material hemoglobin are carried out, the globin powder is prepared by supernatant by concentration and drying; and the hemachrome is prepared by precipitation and crystallization. The method of the invention can fully utilize the precious protein resources of poultry blood, jointly extract the hemachrome and eatable discolored globin powder and has not waste; the obtained discolored globin powder has good color, few impurities and high content of proteins. The method has the advantages of simple operation, low lost and clean without contamination, and being suitable for industrial production.

The invention relates to a method for detecting the necrosis degree of hepatic cells through the level of plasma free DNA, and belongs to the technical field of biology. In the method, through the separation and extraction method and quantification of the plasma free DNA, the necrosis degree of the hepatic cells is reflected by the level of the free DNA. The method comprises the following steps of: preparing a primer beta-globin serving as a standard substance; extracting the plasma DNA in a plasma specimen of hepatopath; performing a real-time fluorescent quantitative polymerase chain reaction on the plasma DNA extracted in the plasma specimen; and measuring and calculating the concentration of the plasma free DNA. The method provides a new diagnostic index for the diagnosis of severe hepatitis.

The present inventors concerns vectors carrying a truncated chimeric CMV-chicken β-actin (smCBA) promoter in which the hybrid chicken β-actin/rabbit β-globin intron is greatly shortened, and their use to deliver to an operatively linked polynucleotide to host cells in vitro or in vivo, resulting in expression of the polynucleotide in the host cells. In one embodiment, the vector carrying the smCBA promoter is administered to the eye. In another embodiment, the vector carrying the smCBA promoter is a self-complementary adeno-associated virus (AAV). The AAV vector may be of any serotype (e.g., type 1, type 2, type 3, type 4, type 5, type 6, type 7, type 8, type 9, type 10). In another embodiment, a self-complementary vector carrying the smCBA promoter is administered to the eye. Another aspect of the invention concerns host cells carrying a vector of the invention. Another aspect of the invention concerns pharmaceutical composition comprising the vectors or host cells of the invention, and a pharmaceutically acceptable carrier.

An sgRNA editing 41/42 deletion mutation site of beta globin gene edit based on CRISPR/Cas9 technology is provided, and that nucleotide sequence thereof is shown as SEQ ID NO.1. The invention also provides a carrier associated therewith, a cell, a gene edit kit and application thereof, in particular a method for editing the 41/42 deletion mutation site of the beta globin gene based on the CRISPR/Cas9 technology, comprising constructing a CRISPR/Cas9 expression vector using sgRNA having a nucleotide sequence as shown in SEQ ID NO:1. The invention can specifically induce the traceless directional modification of gene mutation sites in beta globin gene 41/42 thalassemia, can selectively introduce single allele and double allele sequence changes with high efficiency and precision, and greatlypromotes the improvement of precise repair.

Provided are an expression vector for an animal cell including a promoter, a cloning site or a polynucleotide encoding foreign product, and a transcription terminator, all of which are operably connected each other within the expression vector, in which at least one copy of human β-globin MAR sequence is attached to the 3′ terminal of the transcription terminator, and a method of expressing a foreign gene using the expression vector.

The invention relates to a bicistronic mRNA coexpression gene transporter and a preparation method thereof. The gene order of the gene transporter is SEQ ID No. 15; the gene transporter from 5' end to 3' end comprises bovine Nuclear matrix binding region MAR, artificially constructed combined promoter CAG, Profilin gene FSTN, internal ribosome entry site (IRES), green fluorescent protein AcGFP gene and Rabbit globin poly A signal region; the preparation method comprises the following steps: constructing a carrier pCAG-IRES2-AcGFP1; obtaining FSTN gene and inserting the pCAG-IRES2-AcGFP1 carrier; obtaining the sequence of MAR and inserting the pCAG-IRES2-AcGFP1 carrier; constructing a plasmid carriers so as to obtain the bicistronic mRNA coexpression gene transporter. The gene transporter is not only pure and safe gene transporter but also realizes dual-gene coexpression in any combination, achieves the purpose of multi-gene coexpression through repeated utilization of IRES, and provides new thinking and route for improving the shape of dual or multiple gene control such as economic character.

The present invention provides therapeutic mammalian cells which synthesize and express SS hemoglobin and a tumoricidal transgene. They are produced by transduction of SS erythroid progenitors/erythroblasts using viral vectors comprising a tumoricidal transgene operatively linked to the coding region of SS β-globin promoter/enhancer. Such transduced SS erythroid cells differentiate into mature SSRBCs that exhibit sustained synthesis and expression of SS hemoglobin, a tumoricidal protein(s). Both mature and progenitor SS-cells carrying tumoricidal transgene(s) are capable of selectively localizing in tumor microenvironment, occluding tumor microvessels and inducing a tumoricidal response.

The invention discloses a kit for detecting helicobacter pylori drug resistance gene polymorphism by a multiplex fluorescence PCR melting curve method. The helicobacter pylori drug resistance gene comprises the following three genes: a 23S rRNA gene, a 16S rRNA gene and a gyr A gene, the kit comprises a nucleic acid extraction reagent and a nucleic acid amplification reagent, the nucleic acid extraction reagent comprises superparamagnetic silicon oxide nano magnetic beads, a lysis solution, a washing solution and an eluent; the nucleic acid amplification reagent comprises a primer pair and a probe which respectively correspond to the helicobacter pylori drug resistance gene 23S rRNA gene, the helicobacter pylori 16S rRNA gene, the gyr A gene and an internal standard gene human housekeepinggene beta-globin. According to the invention, three drug-resistant sites and one internal standard gene can be simultaneously detected in a single tube, so that the detection flux of a sample is improved; meanwhile, interference between multiple pairs of primer probes in a detection system is improved, and the sensitivity and specificity of reagent detection are effectively improved.

The invention relates to angiotensin I converting enzyme activity inhibiting oligopeptides as well as a preparation method and application thereof. The method comprises the following steps: taking fresh pig blood as a raw material, extracting globin powder, carrying out enzymolysis on the globin powder and separating and purifying the globin with dissolvable proteolysis fluid to obtain oligopeptides the amino acid sequence of which is Thr Lys ThrTyr Phe Pro His Phe. The experiment proves that the angiotensin I transferase activity inhibiting oligopeptides is an effective angiotensin I converting enzyme inhibitor (ACEI), has the advantages of no toxic and side effects, high safety and low cost, can be subject to industrialization and can be widely used for preparing the medicine and health care products for reducing the hypertension.

The orphan nuclear receptors TR2 and TR4 together constitute the DNA binding core of the 540 kDa DRED complex, a putative repressor of the human embryonic ε- and fetal γ-globin genes. Here the functional consequences of TR2 and TR4 germ line loss of function were examined, transgenic gain of function and dominant negative gain of function on human and murine β-type globin gene expression throughout development. ε-globin transcription responded in a manner consistent with the hypothesis that TR2/TR4 is a constitutive erythroid ε-globin repressor. In contrast, parallel experiments show that TR2/TR4 is a definitive stage-selective γ-globin repressor. This developmental stage-specific, gene-selective repression of the ε- and γ-globin genes by TR2/TR4 establishes, when considered in concert with the competition hypothesis, a coherent molecular rationale for hemoglobin switching (temporally specific, sequential activation of all the β-type globin genes) during vertebrate development.

The invention discloses a lentiviral vector suitable for gene therapy of thalassemia and sickle anemia. The lentiviral vector comprises a beta globin expression cassette; the expression cassette comprises a micro-locus control area, a gene sequence of a beta globin, a promoter sequence of a flank of the upstream of the gene sequence of the beta globin, and a flanking sequence of the downstream ofthe gene sequence of the beta globin; the micro-locus control area is a micro-control element which is screened out from the locus control area of beta globin 16kb and does not contain an HS1 area. Compared with the prior art, the screened beta globin expression cassette has both efficiency and specificity, and does not cause reduction of lentivirus titer; a screened insulator sequence which comesfrom foamy virus and is only 36 bp does not contain a hidden RNA splicing signal, and has the functions of maintaining gene expression and preventing gene activation in a region where the insulator sequence is located; the lentiviral vector can be used for gene therapy of thalassemia and sickle anemia.

Purpose: To provide a blood purifier having a high water permeability, for use in treatment of chronic renal failure, which is not variable in performance during the treatment, independently of a patient's body condition.

Solution: The present invention provides a hollow fiber membrane excellent in performance stability, which has an average thickness of from 10 to 50 μm and an average pore radius of from 150 to 300 Å, and which shows a pure water permeability of 150 to 1,500 mL/m²/hr./mmHg at 37° C., characterized in that the ratio of the overall mass transfer coefficient (Koβ2) of a blood plasma solution of β2-microgloburin to the overall mass transfer coefficient (Komyo) of an aqueous myoglobin solution (i.e., Koβ2/Komyo) is from 0.7 to 1.0.

The invention relates to a method for extracting hemin and globin by the use of leech protease with animal blood as a raw material. The method comprises the following main steps of: 1, carrying out middle-temperature extraction to prepare leech protease for later use; 2, taking fresh animal blood, carrying out anticoagulation treatment, centrifuging and collecting hemoglobin cells; 3, adding one time of pure water, carrying out ultrasonic treatment and breaking cells; 4, filtering through a screen mesh, leaving a filtrate, and adjusting pH value; 5, adding leech protease for enzymatic hydrolysis; 6, adjusting pH value of an enzymatic hydrolysis liquid and carrying out centrifugal separation; and 7, washing a sediment which has undergone centrifugation, carrying out dehydrolysis and drying to obtain hemin; letting a supernatant which has undergone centrifugation pass through a microfiltration membrane to remove impurities, using a nanofiltration membrane for concentration, and carrying out dehydrolysis and drying on a concentrate to obtain globin. According to the invention, animal blood resources are fully utilized and the leech extract product is used as an enzyme preparation to produce hemin and globin with high added values. The technology is simple and easy to operate, the production cost is low, and the method is suitable for industrial production.

The present invention provides methods for increasing endogenous globin expression in a subject, specifically γ-globin expression. The invention also provides compounds and medicaments for use in the methods. The methods are particularly useful for increasing fetal hemoglobin production in a subject, and can be used to treat various disorders, e.g., β thalassemia and sickle cell disease.